1.0 CEUs
Complexities of Long-Acting Agents for
Prevention and Treatment
Module Description Designed for the HIV healthcare professional, this webinar, part two of our LAA Series, will examine long-acting HIV treatments and the barriers to increasing awareness, utilization and implementation. We aim to examine practical considerations for healthcare providers, including patient selection, dosing regimens and monitoring protocols. We will also analyze the current challenges and define strategies to overcome barriers in implementing long-acting agents for HIV prevention and treatment to optimize patient outcomes.
Credit Dates 4/21/2024 – 4/20/2025
Jointly provided by Partners for Advancing Clinical Education (PACE) and the American Academy of HIV Medicine.
This activity is supported by an independent educational grant from ViiV.
Jointly provided by Partners for Advancing Clinical Education (PACE) and the American Academy of HIV Medicine.
This activity is supported by an independent educational grant from ViiV.
Learning Objectives
- Identify several of the challenges of implementation of Long-Acting Injectable (LAI) antiretroviral HIV treatment and prevention in clinical practice
- Assess the impact of demographic and geographic disparities on LAI uptake
- Incorporate variations in preferences for LAI PrEP among different populations
Target Audience This activity is intended for physicians, PAs, NPs, RNs, and pharmacists who are engaged in the care of people with HIV.
Estimated Time to Complete the Activity: 1 hour
Presenter: M. Keith Rawlings, MD
Instructions for Credit There are no fees for participating and receiving CME/CE credit for this activity.
Participation in this self-study activity should be completed in approximately 1.0 hour. To successfully complete this activity and receive CE credit, learners must follow these steps during the period from April 21, 2024 through April 20, 2025:
- Review the objectives and disclosures
- Study the educational content
- Visit https://www.paceducation.com/LAAenduringApril
- Complete the activity evaluation
If you have questions regarding the certification of this activity, please contact PACE by emailing customersupport@paceducation.com.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the American Academy of HIV Medicine. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Education PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit (s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education PACE designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number-JA4008073-9999-24-072-H02-P
Type of Activity: Knowledge
Continuing Nursing Education The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours. Designated for 0.25 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Disclosure of Conflict of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr. M. Keith Rawlings, faculty for this activity, previously served as an advisor, consultant and employee to ViiV Healthcare and Gilead Sciences and owns stock in both Gilead Sciences and GlaxoSmithKline.
Planners and Managers
The PACE planners and managers have no relevant financial relationships.
The Academy planners and managers have no relevant financial relationships.
Media: Internet
Computer System Requirements
This program requires the use of an internet-connected computer or device and a modern web browser capable of streaming video.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Continuing Nursing Education The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours. Designated for 0.25 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Disclosure of Conflict of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr. M. Keith Rawlings, faculty for this activity, previously served as an advisor, consultant and employee to ViiV Healthcare and Gilead Sciences and owns stock in both Gilead Sciences and GlaxoSmithKline.
Planners and Managers
The PACE planners and managers have no relevant financial relationships.
The Academy planners and managers have no relevant financial relationships.
Media: Internet
Computer System Requirements
This program requires the use of an internet-connected computer or device and a modern web browser capable of streaming video.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
